ARTICLE | Clinical News
CDX-1401: Phase I/II started
September 21, 2009 7:00 AM UTC
Celldex began an open-label, dose-escalation, U.S. Phase I/II trial in about 36 patients to evaluate 3 dosages of subcutaneous CDX-1401 given every 2 weeks for 4 doses in combination with resiquimod, ...